Keywords: SYNGIS Pharma, Restructuring, CEO leaving

Germany’s SYGNIS Pharma announces strategic restructuring; CEO leaving

Article | 01 November 2010

Print This

German development-stage biotech firm SYGNIS Pharma AG (Frankfurt: LIO) saw its share price fall 7.9% to 0.65 euros on Friday, after the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in